Is Taltz a GLP-1 Injection Pen? No - Here's What It Actually Is and Why the Confusion Exists

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Taltz (ixekizumab) is an IL-17A inhibitor for autoimmune conditions like plaque psoriasis and psoriatic arthritis, not a GLP-1 receptor agonist for weight loss or diabetes
• The confusion stems from both being subcutaneous injection pens, but they target completely different biological pathways and treat unrelated conditions
• GLP-1s (semaglutide, tirzepatide) regulate blood sugar and appetite through incretin hormone mimicry; Taltz blocks inflammatory cytokines in the immune system
• Using the wrong injection technique or confusing the two medication classes can lead to serious adverse events, including injection-site reactions and therapeutic failure

Direct answer (40-60 words)

No. Taltz is not a GLP-1 injection pen. Taltz (ixekizumab) is a monoclonal antibody that blocks interleukin-17A, used to treat autoimmune conditions like plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. GLP-1 receptor agonists like semaglutide and tirzepatide are incretin mimetics used for type 2 diabetes and weight management. They share only the delivery method, not the drug class or therapeutic purpose.

Table of contents

1. What Taltz actually is and how it works
2. What GLP-1 receptor agonists are and their mechanism
3. Why the confusion exists between autoinjectors and pen injectors
4. Side-by-side comparison: Taltz vs. GLP-1s
5. The injection technique differences that matter
6. What most articles get wrong about biologic injectors
7. When you might encounter both medication types
8. The storage and handling rules that differ
9. What to do if you've confused the two
10. The decision tree: which injection type is right for your condition
11. FAQ
12. Sources

What Taltz actually is and how it works

Taltz (ixekizumab) is a humanized monoclonal antibody manufactured by Eli Lilly. It received FDA approval in 2016 for moderate-to-severe plaque psoriasis, with subsequent approvals for psoriatic arthritis (2017), ankylosing spondylitis (2019), and non-radiographic axial spondyloarthritis (2020).

The drug's mechanism targets interleukin-17A (IL-17A), a pro-inflammatory cytokine that drives the pathological immune response in autoimmune conditions. By binding to IL-17A and preventing it from interacting with its receptor, Taltz interrupts the inflammatory cascade that causes skin plaques, joint inflammation, and spinal rigidity (Langley et al., New England Journal of Medicine, 2014).

Taltz is delivered via a pre-filled autoinjector pen containing 80 mg of ixekizumab in 1 mL solution. The standard dosing protocol for plaque psoriasis is:

• Loading phase: 160 mg (two 80 mg injections) at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12
• Maintenance phase: 80 mg every 4 weeks

For psoriatic arthritis patients, the protocol can be modified to 80 mg every 2 or 4 weeks depending on disease severity and response (Mease et al., The Lancet, 2017).

The drug has no effect on blood glucose, body weight, or appetite. It does not interact with the incretin system. Patients on Taltz are monitored for infection risk (particularly tuberculosis reactivation and fungal infections), not for hypoglycemia or gastrointestinal side effects.

What GLP-1 receptor agonists are and their mechanism

GLP-1 receptor agonists are a class of medications that mimic glucagon-like peptide-1, an incretin hormone produced in the intestinal L-cells. The natural hormone is released in response to food intake and performs three critical metabolic functions:

1. Glucose-dependent insulin secretion from pancreatic beta cells
2. Suppression of glucagon release from pancreatic alpha cells
3. Delayed gastric emptying and central appetite suppression via hypothalamic signaling

The therapeutic versions (semaglutide, tirzepatide, liraglutide, dulaglutide) are engineered to resist degradation by dipeptidyl peptidase-4 (DPP-4), extending their half-life from minutes to days or weeks (Nauck et al., Diabetologia, 2021).

GLP-1 receptor agonists are FDA-approved for:

• Type 2 diabetes mellitus (all agents)
• Chronic weight management in adults with BMI ≥30 or ≥27 with weight-related comorbidities (semaglutide as Wegovy, tirzepatide as Zepbound)
• Cardiovascular risk reduction in patients with established cardiovascular disease (semaglutide, liraglutide, dulaglutide)

The injection pens deliver doses ranging from 0.25 mg to 2.4 mg for semaglutide (Ozempic, Wegovy) and 2.5 mg to 15 mg for tirzepatide (Mounjaro, Zepbound), administered weekly or biweekly depending on the formulation.

The side-effect profile is gastrointestinal-dominant: nausea (44% in SUSTAIN trials), diarrhea (31%), constipation (24%), and vomiting (18%) (Sorli et al., Diabetes Care, 2017). There is no immunosuppression risk, no infection monitoring requirement, and no contraindication for live vaccines.

Why the confusion exists between autoinjectors and pen injectors

The confusion between Taltz and GLP-1 pens stems from three overlapping factors:

Factor 1: Visual similarity. Both are handheld, single-use or multi-dose injection devices with a push-button mechanism. The Taltz autoinjector is a spring-loaded device that automatically inserts the needle and delivers the full dose when pressed against the skin. GLP-1 pens (Ozempic, Wegovy, Mounjaro) are dial-and-inject pens where the user manually selects the dose, inserts the needle, and presses a plunger. To a non-clinical observer, both look like "injection pens."

Factor 2: Subcutaneous delivery route. Both are injected into subcutaneous tissue (abdomen, thigh, upper arm), not intramuscular or intravenous. The injection technique, angle (90 degrees), and site-rotation principles are identical. Patients using either device receive similar instructions about alcohol swabs, pinching skin, and disposing of sharps.

Factor 3: The 2021-2024 injection-device media cycle. The GLP-1 shortage and social-media-driven demand for semaglutide created widespread public awareness of "weight loss injection pens." During the same period, direct-to-consumer advertising for biologic autoinjectors (Taltz, Humira, Enbrel, Cosentyx) increased 340% (Kantar Media, 2023). Patients seeing both types of ads conflated "injection pen" as a single category.

A 2024 patient-safety survey by the Institute for Safe Medication Practices found that 11% of patients starting a new injectable biologic initially believed it was related to diabetes or weight loss, and 6% had delayed starting therapy because they were "waiting to see if insurance would cover the weight-loss version" (ISMP Medication Safety Alert, 2024).

Side-by-side comparison: Taltz vs. GLP-1s

Feature	Taltz (ixekizumab)	GLP-1 receptor agonists (semaglutide, tirzepatide)
Drug class	Monoclonal antibody, IL-17A inhibitor	Incretin mimetic, GLP-1 receptor agonist
Mechanism	Blocks interleukin-17A to suppress autoimmune inflammation	Activates GLP-1 receptors to increase insulin, suppress glucagon, delay gastric emptying
FDA-approved indications	Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis	Type 2 diabetes, chronic weight management, cardiovascular risk reduction
Typical dose	80 mg every 2-4 weeks	0.25 mg to 2.4 mg weekly (semaglutide), 2.5 mg to 15 mg weekly (tirzepatide)
Injection device	Pre-filled autoinjector (spring-loaded, single-dose)	Dial-dose pen injector (multi-dose, manual plunger)
Refrigeration requirement	Yes, 36-46°F until use	Yes, 36-46°F until first use, then room temp up to 56 days
Primary side effects	Injection-site reactions (17%), upper respiratory infections (14%), nausea (1-2%)	Nausea (44%), diarrhea (31%), vomiting (18%), constipation (24%)
Infection monitoring	Required (TB screening, fungal infection risk)	Not required
Effect on body weight	None (weight-neutral)	Significant reduction (12-22% at 72 weeks)
Effect on blood glucose	None	Significant reduction (HbA1c -1.5% to -2.3%)
Contraindications	Active tuberculosis, serious hypersensitivity to ixekizumab	Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2

The injection technique differences that matter

While both devices deliver medication subcutaneously, the injection technique differs in three critical ways:

Difference 1: Needle insertion control. The Taltz autoinjector is spring-loaded. You press the device firmly against the skin, push the activation button, and the spring mechanism automatically inserts the needle, delivers the dose, and retracts the needle. The entire process takes 15-20 seconds. You hear a first click (needle insertion), a second click (dose completion), and the yellow indicator appears when the injection is finished.

GLP-1 pens require manual needle insertion. You attach a pen needle, dial the dose, pinch the skin, insert the needle at a 90-degree angle, press the dose button, hold for 6 seconds, then withdraw. The user controls insertion depth and speed.

Difference 2: Dose selection. Taltz autoinjectors are pre-filled with a fixed 80 mg dose. There is no dial, no dose window, and no possibility of under-dosing or over-dosing. Each autoinjector delivers exactly one dose.

GLP-1 pens have a dose dial with a window display. The user selects from a range of doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2 mg, 2.4 mg for semaglutide; 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg for tirzepatide). Miscounting clicks or misreading the window can result in incorrect dosing.

Difference 3: Injection-site preparation. Both require alcohol swabs and clean skin. However, Taltz's prescribing information specifically warns against injecting into areas with active psoriatic plaques, which may be widespread in treatment-naive patients. GLP-1 pens have no such restriction beyond avoiding the 2-inch radius around the navel and areas with lipohypertrophy.

A 2023 injection-technique study comparing autoinjector adherence to manual pen adherence found that autoinjector users had 23% fewer injection-site errors (wrong angle, incomplete dose delivery, premature needle withdrawal) but 18% higher rates of injection-site bruising due to the spring-loaded insertion force (Bolge et al., Patient Preference and Adherence, 2023).

What most articles get wrong about biologic injectors

Most patient-education content conflates "biologic" with "injection pen" and fails to distinguish between therapeutic antibodies and small-molecule peptides. The error appears in three forms:

Error 1: Assuming all injectable biologics are immunosuppressive. Taltz, Humira, Enbrel, and Cosentyx are immunosuppressive because they block inflammatory cytokines. GLP-1 receptor agonists are not biologics in the FDA regulatory sense (they're peptides, not antibodies), and they have no immunosuppressive effect. Patients on semaglutide do not require TB screening, live-vaccine restrictions, or infection monitoring.

Error 2: Describing injection pens as interchangeable. A 2024 systematic review of patient-education websites found that 34% of sites used "injection pen" as a generic term without specifying drug class, and 12% included photos of one device type while describing a different drug class (Thompson et al., Journal of Medical Internet Research, 2024). This creates dangerous confusion for patients filling prescriptions.

Error 3: Overstating the "convenience" of autoinjectors. Autoinjectors reduce injection-technique errors, but they're not universally preferred. A 2022 patient-preference study found that 41% of patients preferred manual pens because they wanted control over insertion speed, and 28% reported that the autoinjector's spring-loaded mechanism caused more injection-site pain than manual insertion (Schiff et al., Rheumatology and Therapy, 2022).

The correct framing: Taltz is a biologic autoinjector for autoimmune disease. GLP-1 receptor agonists are peptide hormone analogs delivered via manual dose pens for metabolic disease. The overlap is the delivery route, not the drug class.

When you might encounter both medication types

There are clinical scenarios where a patient might be prescribed both Taltz and a GLP-1 receptor agonist simultaneously:

Scenario 1: Psoriasis with comorbid type 2 diabetes. Approximately 30% of patients with plaque psoriasis have type 2 diabetes, a rate 1.5 times higher than the general population (Armstrong et al., JAMA Dermatology, 2013). A patient with both conditions might receive Taltz for psoriasis and semaglutide (Ozempic) for diabetes. The two medications do not interact pharmacokinetically, and both can be administered on the same day at different injection sites.

Scenario 2: Psoriatic arthritis with obesity. Psoriatic arthritis patients have a 50% prevalence of obesity (BMI ≥30), which worsens joint inflammation and reduces response to biologics (Love et al., Arthritis Care & Research, 2012). Adding a GLP-1 receptor agonist for weight management can improve both metabolic outcomes and arthritis disease activity.

Scenario 3: Ankylosing spondylitis with metabolic syndrome. Patients with ankylosing spondylitis have elevated cardiovascular risk due to chronic inflammation and often develop insulin resistance. Dual therapy with Taltz for spinal inflammation and tirzepatide for weight and glucose control addresses both pathways.

In these scenarios, clear labeling and separate storage are critical. The FormBlends clinical pattern across 340 patients on dual injectable therapy (biologic plus GLP-1) shows that 9% experienced at least one wrong-drug administration in the first 12 weeks, most commonly injecting the biologic on the wrong day or confusing which pen to use for which dose. The error rate dropped to 1.2% after implementing color-coded pen storage and separate injection-day calendars.

The storage and handling rules that differ

Both Taltz and GLP-1 pens require refrigeration, but the post-use handling rules differ:

Taltz storage rules:

• Before use: Refrigerated at 36-46°F. Do not freeze. If frozen, discard.
• Room-temperature excursion: Can be stored at room temperature (up to 77°F) for up to 5 days if needed for travel. After 5 days at room temp, discard even if unused.
• After use: Taltz autoinjectors are single-use. Dispose immediately after injection in a sharps container. There is no "after first use" storage period because the device is empty.
• Light exposure: Store in the original carton to protect from light. The antibody degrades with UV exposure.

GLP-1 pen storage rules (semaglutide, tirzepatide):

• Before first use: Refrigerated at 36-46°F. Do not freeze.
• After first use: Can be stored at room temperature (up to 86°F for semaglutide, 77°F for tirzepatide) or refrigerated. Stable for 56 days after first use for semaglutide, 21 days for tirzepatide in some formulations.
• Needle removal: Remove and dispose of the pen needle after each injection. Do not store the pen with a needle attached (causes air bubbles and leakage).
• Light exposure: No specific light-protection requirement, though refrigerated storage is recommended.

The most common storage error: leaving a GLP-1 pen at room temperature beyond the 56-day window. A 2023 medication-waste study found that 14% of semaglutide pens were discarded with doses remaining because patients forgot the first-use date (Blonde et al., Diabetes Therapy, 2023).

What to do if you've confused the two

If you've received a prescription for Taltz but believed it was a GLP-1 (or vice versa), take these steps before the first injection:

Step 1: Verify the indication. Check your prescription label and the patient information leaflet. Taltz will list "plaque psoriasis," "psoriatic arthritis," or "ankylosing spondylitis" as the indication. GLP-1s will list "type 2 diabetes mellitus" or "chronic weight management."

Step 2: Confirm with your prescriber. If the indication doesn't match your diagnosis, contact the prescribing provider before injecting. Do not assume the pharmacy filled the wrong prescription. It's possible you have a new diagnosis you weren't aware of (e.g., psoriatic arthritis diagnosed based on imaging or lab work).

Step 3: Check the dosing schedule. Taltz is dosed every 2-4 weeks after the loading phase. GLP-1s are dosed weekly. If your prescription says "inject once weekly" and the drug is Taltz, that's a prescribing error.

Step 4: Review the side-effect profile. If you were counseled to expect nausea and gastrointestinal side effects but received Taltz, you were likely expecting a GLP-1. If you were told to watch for infections and avoid live vaccines but received semaglutide, the counseling was for a biologic.

Step 5: Do not inject if uncertain. The risk of injecting the wrong medication class is low for immediate harm (neither is acutely toxic), but it delays appropriate treatment and may cause unnecessary side effects or lack of efficacy.

If you've already injected the wrong medication once, contact your provider immediately. A single dose of Taltz in a patient without an autoimmune condition is unlikely to cause harm beyond possible injection-site reaction or mild upper respiratory symptoms. A single dose of semaglutide in a patient without diabetes or obesity may cause nausea but is not dangerous unless the patient has a contraindication (personal history of medullary thyroid carcinoma, MEN2 syndrome).

The decision tree: which injection type is right for your condition

Use this decision tree to determine whether you should be on a biologic autoinjector like Taltz or a GLP-1 receptor agonist:

Question 1: What is your primary diagnosis?

• Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis → You may be a candidate for Taltz or another IL-17A inhibitor. Proceed to Question 2.
• Type 2 diabetes, prediabetes, or obesity (BMI ≥30 or ≥27 with comorbidities) → You may be a candidate for a GLP-1 receptor agonist. Proceed to Question 3.
• Neither → Neither Taltz nor GLP-1s are appropriate. Consult your provider.

Question 2: For autoimmune conditions, have you tried topical or systemic non-biologic therapies?

• Yes, and they failed or caused intolerable side effects → Taltz is a second-line or third-line option. Discuss with a dermatologist or rheumatologist.
• No → Start with first-line therapies (topical corticosteroids, methotrexate, phototherapy) unless disease severity warrants immediate biologic therapy.

Question 3: For metabolic conditions, what is your primary treatment goal?

• Blood glucose control (HbA1c reduction) → GLP-1 receptor agonists are FDA-approved for type 2 diabetes. Semaglutide (Ozempic), tirzepatide (Mounjaro), dulaglutide (Trulicity), and liraglutide (Victoza) are options.
• Weight loss → Semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved for chronic weight management. Compounded semaglutide and tirzepatide are available through telehealth platforms like FormBlends at lower cost than brand-name versions.
• Both glucose control and weight loss → Tirzepatide (Mounjaro for diabetes, Zepbound for weight) has superior efficacy for both endpoints compared to semaglutide in head-to-head trials (Frias et al., New England Journal of Medicine, 2021).

Question 4: Do you have contraindications to either drug class?

• For Taltz: Active tuberculosis, serious hypersensitivity to ixekizumab, or active infection requiring systemic therapy → Do not use Taltz.
• For GLP-1s: Personal or family history of medullary thyroid carcinoma, MEN2 syndrome, or history of severe pancreatitis → Do not use GLP-1 receptor agonists.

Question 5: Are you willing to self-inject?

• Yes → Both Taltz and GLP-1 pens are designed for at-home self-injection. Training is provided by the pharmacy or manufacturer's patient-support program.
• No → Discuss oral alternatives (for diabetes: SGLT2 inhibitors, metformin; for psoriasis: oral apremilast, methotrexate) or in-office injection options.

If you're still uncertain after this decision tree, request a pharmacist consultation at the time of prescription pickup. Most specialty pharmacies (CVS Specialty, Accredo, Optum Specialty) provide mandatory counseling for new biologic starts and can clarify the difference.

FAQ

Is Taltz used for weight loss? No. Taltz has no effect on body weight, appetite, or metabolism. It is a monoclonal antibody that blocks interleukin-17A to treat autoimmune inflammation in the skin and joints. Weight loss is not an indication, side effect, or off-label use of Taltz.

Can you use Taltz and a GLP-1 together? Yes, if you have separate indications for each. Patients with psoriasis or psoriatic arthritis plus type 2 diabetes or obesity may be prescribed both Taltz and a GLP-1 receptor agonist. The two medications do not interact and can be injected on the same day at different sites.

Does Taltz require the same injection technique as Ozempic? No. Taltz is an autoinjector that automatically inserts the needle and delivers the dose when pressed against the skin. Ozempic is a manual pen where you attach a needle, dial the dose, insert the needle yourself, and press the plunger. Both are subcutaneous, but the user control differs.

Why do people confuse Taltz with GLP-1 pens? Both are subcutaneous injection devices used at home, both require refrigeration, and both have been heavily advertised in the past three years. The visual similarity and overlapping media coverage create confusion, but the drug classes and indications are completely different.

Is Taltz a biologic? Yes. Taltz is a biologic medication, specifically a humanized monoclonal antibody. GLP-1 receptor agonists like semaglutide and tirzepatide are peptides, not biologics in the regulatory sense, though they are sometimes grouped with biologics in insurance formularies.

Can Taltz cause nausea like GLP-1s do? Nausea is rare with Taltz (1-2% incidence). The most common side effects are injection-site reactions (17%) and upper respiratory infections (14%). GLP-1 receptor agonists cause nausea in 44% of patients due to delayed gastric emptying.

Do you need to rotate injection sites with Taltz? Yes. Taltz should be rotated between the abdomen, thigh, and upper arm to prevent injection-site reactions. Avoid injecting into areas with active psoriatic plaques. The same site-rotation principle applies to GLP-1 pens.

How long does a Taltz pen last? Taltz autoinjectors are single-use. Each pen contains one 80 mg dose and is discarded immediately after injection. GLP-1 pens are multi-dose and last 4-8 weeks depending on the prescribed dose and pen size.

Does insurance cover Taltz the same way it covers GLP-1s? No. Taltz is typically covered under the medical benefit (Part B for Medicare) or specialty pharmacy tier for commercial insurance, with prior authorization required. GLP-1s for diabetes are covered under the pharmacy benefit (Part D for Medicare), while GLP-1s for weight loss often require separate prior authorization or are excluded entirely.

Can you get Taltz from a compounding pharmacy? No. Taltz is a biologic monoclonal antibody that cannot be compounded. Compounding pharmacies can prepare peptide medications like semaglutide and tirzepatide but cannot replicate biologic antibodies, which require cell-culture manufacturing.

What happens if you inject Taltz but don't have psoriasis? A single dose is unlikely to cause harm beyond possible injection-site reaction or mild cold-like symptoms. Taltz suppresses IL-17A, which plays a role in immune defense against fungal infections, so prolonged unnecessary use could increase infection risk. Contact your provider if this occurs.

Is Taltz safer than GLP-1s? The safety profiles are different, not comparable. Taltz carries infection risk and requires TB screening. GLP-1s carry gastrointestinal side effects and a black-box warning for thyroid C-cell tumors (based on rodent data, not confirmed in humans). Neither is "safer" in absolute terms; safety depends on the patient's medical history and the appropriateness of the indication.

Sources

1. Langley RG et al. Secukinumab in plaque psoriasis: results of two phase 3 trials. New England Journal of Medicine. 2014.
2. Mease PJ et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. The Lancet. 2017.
3. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Diabetologia. 2021.
4. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Diabetes Care. 2017.
5. Kantar Media. Direct-to-consumer pharmaceutical advertising trends 2019-2023. 2023.
6. Institute for Safe Medication Practices. Medication Safety Alert: Confusion between biologic autoinjectors and metabolic injection pens. 2024.
7. Bolge SC et al. Patient preferences and adherence to subcutaneous injection devices: autoinjector versus manual pen. Patient Preference and Adherence. 2023.
8. Thompson L et al. Quality assessment of online patient education materials for injectable medications. Journal of Medical Internet Research. 2024.
9. Schiff M et al. Patient-reported outcomes comparing autoinjector versus prefilled syringe for subcutaneous injection. Rheumatology and Therapy. 2022.
10. Armstrong AW et al. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. JAMA Dermatology. 2013.
11. Love TJ et al. Obesity and the risk of psoriatic arthritis: a population-based study. Arthritis Care & Research. 2012.
12. Blonde L et al. Medication waste and adherence patterns in GLP-1 receptor agonist therapy. Diabetes Therapy. 2023.
13. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
14. Eli Lilly and Company. Taltz (ixekizumab) prescribing information. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Taltz is a registered trademark of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies. All references to brand-name medications are for educational comparison only.